D. Nicholls

发表

1,2-Dihydro-4-quinazolinamines: potent, highly selective inhibitors of inducible nitric oxide synthase which show antiinflammatory activity in vivo.

A. Tinker, H. Beaton, N. Boughton-Smith, 2003, Journal of medicinal chemistry.

2-aminopyridines as highly selective inducible nitric oxide synthase inhibitors. Differential binding modes dependent on nitrogen substitution.

J. Tainer, R. Rosenfeld, A. Arvai, 2004, Journal of medicinal chemistry.

Impact of a five-dimensional framework on R&D productivity at AstraZeneca

David J. Nicholls, Jerome T. Mettetal, Steve Rees, 2018, Nature Reviews Drug Discovery.

Malate dehydrogenase: A model for structure, evolution, and catalysis

D J Nicholls, C. R. Goward, D. Nicholls, 1994, Protein science : a publication of the Protein Society.

From libraries to candidate: the discovery of new ultra long-acting dibasic β₂-adrenoceptor agonists.

G. Pairaudeau, A. Bailey, E. Cadogan, 2012, Bioorganic & medicinal chemistry letters.

Design driven HtL: The discovery and synthesis of new high efficacy β₂-agonists.

G. Pairaudeau, A. Bailey, E. Cadogan, 2011, Bioorganic & medicinal chemistry letters.

Agonist‐specific patterns of β2‐adrenoceptor responses in human airway cells during prolonged exposure

C. Sköld, D. Nicholls, Eylem Gürcan, 2009, British journal of pharmacology.

Erwinia chrysanthemi L-asparaginase: epitope mapping and production of antigenically modified enzymes.

D J Nicholls, T. Atkinson, M. Scawen, 1994, The Biochemical journal.

AZD3199: A potent and selective β2-adrenergic receptor agonist with rapid onset of action

R. Austin, G. Pairaudeau, D. Nicholls, 2011, ATS 2011.

The In Vivo Profile Of AZD3199: A Novel, Fast Acting B2-Agonist With A Long Duration Of Action

G. Pairaudeau, D. Nicholls, S. Connolly, 2011, ATS 2011.

Pharmacological Characterization of AZD5069, a Slowly Reversible CXCR2 Antagonist.

Alasdair, D. Nicholls, K. Wiley, 2015 .

Formoterol and salmeterol induce a similar degree of β2‐adrenoceptor tolerance in human small airways but via different mechanisms

P. Cooper, D. Nicholls, J. Zhang, 2011, British journal of pharmacology.

Discovery of AZD3199, An Inhaled Ultralong Acting β2 Receptor Agonist with Rapid Onset of Action.

G. Pairaudeau, A. Bailey, E. Cadogan, 2014, ACS medicinal chemistry letters.

Micronucleus induction in the bone marrow of rats by pharmacological mechanisms. II: long-acting beta-2 agonism.

D. Nicholls, M. O’Donovan, C. Fred, 2013, Mutagenesis.

Characteristics of AZD9708, a novel, selective β2-adrenoceptor agonist with rapid onset and long duration of action.

R. Austin, E. Cadogan, D. Nicholls, 2012, Pulmonary pharmacology & therapeutics.

Discovery and evaluation of a novel monocyclic series of CXCR2 antagonists.

R. Austin, D. Nicholls, A. Cook, 2015, Bioorganic & medicinal chemistry letters.

Cloning and nucleotide sequences of themdhandsucDgenes fromThermus aquaticusB

T. Atkinson, N. Minton, D. Nicholls, 1990 .

Cloning and nucleotide sequences of the mdh and sucD genes from Thermus aquaticus B.

T. Atkinson, N. Minton, D. Nicholls, 1990, FEMS microbiology letters.

Thienopyridines: nitric oxide synthase inhibitors with potent in vivo activity.

A. Tinker, H. Beaton, N. Boughton-Smith, 2001, Bioorganic & medicinal chemistry letters.

Pharmacological Characterization of AZD5069, a Slowly Reversible CXC Chemokine Receptor 2 Antagonist

D. Nicholls, K. Wiley, I. Dainty, 2015, The Journal of Pharmacology and Experimental Therapeutics.

Anchored plasticity opens doors for selective inhibitor design in nitric oxide synthase

J. Tainer, E. Getzoff, R. Rosenfeld, 2008, Nature chemical biology.

An investigation of the thermal stabilities of two malate dehydrogenases by comparison of their three-dimensional structures.

T. Atkinson, M. Scawen, D. Nicholls, 1994, Journal of molecular graphics.

Cloning and overexpression of Lactobacillus helveticus D-lactate dehydrogenase gene in Escherichia coli.

T. Atkinson, S. Kochhar, H. Hottinger, 1992, European journal of biochemistry.

Cloning sequencing and over-expression of Escherichia coli malate dehydrogenase

T. Atkinson, N. Minton, D. Nicholls, 1989, Applied Microbiology and Biotechnology.

Substitution of the amino acid at position 102 with polar and aromatic residues influences substrate specificity of lactate dehydrogenase

T. Atkinson, A. Clarke, J. Holbrook, 1994, Journal of protein chemistry.

The importance of arginine 102 for the substrate specificity of Escherichia coli malate dehydrogenase.

T. Atkinson, A. Clarke, J. Holbrook, 1992, Biochemical and biophysical research communications.

A single amino acid mutation enhances the thermal stability of Escherichia coli malate dehydrogenase.

L. Irons, R. O'brien, B. Chowdhry, 1994, European journal of biochemistry.

Dissecting the contributions of a specific side-chain interaction to folding and catalysis of Bacillus stearothermophilus lactate dehydrogenase.

T. Atkinson, A. Clarke, J. Holbrook, 1993, European journal of biochemistry.

Identification of a Putative Intracellular Allosteric Antagonist Binding-Site in the CXC Chemokine Receptors 1 and 2

D. Nicholls, P. Mallinder, T. Wright, 2008, Molecular Pharmacology.

3,4-Dihydro-1-isoquinolinamines: a novel class of nitric oxide synthase inhibitors with a range of isoform selectivity and potency.

A. Tinker, H. Beaton, P. Hamley, 2001, Bioorganic & medicinal chemistry letters.

The discovery of novel, potent and highly selective inhibitors of inducible nitric oxide synthase (iNOS).

Glen Andrews, Paul D Leeson, Anders Åberg, 2011, Bioorganic & medicinal chemistry letters.

Protein engineering of 2‐hydroxy acid dehydrogenases

T. Atkinson, C. R. Goward, M. Scawen, 2007 .

Pharmacological Characterization of AZD 5069 , a Slowly Reversible CXC Chemokine Receptor 2 Antagonist s

D. Nicholls, K. Wiley, I. Dainty, 2015 .

Identification of a Putative Intracellular Allosteric Antagonist Binding-Site in the CXC Chemokine Receptors 1 and 2

D. Nicholls, P. Mallinder, T. Wright, 2008, Molecular Pharmacology.